Patients with diabetes (DM) experience higher rates of in-stent restenosis and therefore greater benefit from drug eluting stent (DES) implant at the time of percutaneous coronary intervention (PCI). DES stent implantation necessitates prolonged dual anti-platelet therapy (DAPT). While DAPT reduces the risk of ischemic events post-PCI, it also increases the risk for bleeding. Whether long-term rates of bleeding differ among patients with and without DM receiving DAPT in real-world practice is unknown.
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INTRODUCTION
Percutaneous coronary intervention (PCI) is a cardiovascular procedure indicated for treatment of significant coronary stenosis and typically involves stent placement in a large coronary artery. This procedure may be indicated in an acute setting, such as during an acute coronary syndrome, or heart attack.
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The procedure may also be indicated for patients with refractory angina, or cardiac-type chest pain, which has not responded to optimal medical management with cardiac medications. 2 The volume of PCIs has steadily risen over the past several decades. 3 Bleeding events following PCI are common and are associated with an increased cost and increased short-and long-term risk of morbidity and mortality. 4, 5 The prevalence and prognosis of bleeding in the first year after PCI was recently described by Amin et al, who
reported that 37.5% of patients reported nuisance bleeding, which was associated with worse quality of life. 6 There are two stent type categories used in PCI procedures: the drug eluting (DES) and the bare metal stent (BMS) ( Table 1) . The DES is a more contemporary device consisting of a metallic stent backbone, antiproliferative drug, and a polymer that serves as the vehicle for drug delivery and drug release. 7 On the other hand, the BMS is composed of a metallic design without an embedded antiproliferative drug. More specifically, patients with DM constitute approximately twenty five percent of all patients undergoing PCI in large clinical trials. 10, 11 There is reason to believe that patients with diabetes, as a result of increased platelet aggregation and hyporesponse to anti platelet medication, may experience bleeding at different rates than patients without diabetes. Prior studies exploring in-stent restenosis following PCI with drug eluting stent (DES) suggest that patients with DM experience higher rates of in-stent restenosis and therefore greater net benefit from DES (as compared with BMS) implant at the time of PCI. 10, [12] [13] [14] As a result, the American Heart Association provides a Class I (highest available) recommendation that patients with DM receive prolonged DAPT following DES placement to decrease risk of late stent thrombosis.
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While DAPT reduces the risk of ischemic events post-PCI, it is known to also increase the risk for bleeding in patients undergoing elective PCI, as well as those undergoing PCI for an indication of acute coronary syndrome. [16] [17] [18] It is unknown, however, whether this risk of bleeding would be generalizable This greater net benefit is hypothesized to be due to patients with DM experiencing greater platelet reactivity. 21 While patients in these trials underwent emergent or urgent PCI for an indication of acute coronary syndrome, it is unknown whether patients with DM incur better bleeding outcomes (versus patients without DM) on prolonged DAPT following PCI for a broader set of indications. It is unknown whether or not long-term bleeding rates differ among patients with and without DM receiving prolonged DAPT (Figure 1 
Measures of Follow-Up Bleeding Data
Within the OPS/PRISM registry data collection process, bleeding events were defined according to standard National Cardiovascular Data Registry definitions (access site bleeding with a hematoma >10 cm for femoral, >5 cm for brachial and >2 cm for radial access).
Additionally, retroperitoneal, gastrointestinal, genitourinary bleeding requiring a transfusion, prolonged hospitalizations or hemoglobin drop of greater than 3 g/dL were prospectively collected as bleeding events. For our observational study, bleeding events were defined according to the Bleeding Academic Research Consortium (BARC) guidelines. Based on the BARC classification system, bleeding event severity is graded zero to five, with zero representing no bleeding and five representing fatal bleeding 22 ( Table 3) . Of note, we interpreted BARC 1 bleeding events to include bruising events and subsequently did a sensitivity analysis excluding self-reported bruising events (BARC ≥1 minus bruising).
As part of the OPS/PRISM study, patients were asked to report interval hospitalizations since their last study contact during the follow-up interviews. At each follow up interview, patients were asked whether they had experienced easy bruising, easy bleeding, occasional nose or gum bleed or serious bleeding since their last interview. If any of these bruising or bleeding outcomes were reported, a follow up question asked patients what they did about this bruising or bleeding. Choices included "didn't tell any doctor", "told doctor, but no treatment", "doctor stopped a medicine or switched to another medicine", "treated with transfusion", or "treated by hospitalization". Patients had the option of selecting all answer choices that applied. All patients were required to have a 12-month follow up assessment for the purposes of the primary analysis. Most patients had at least one additional assessment (most commonly at 6 months post index PCI). If a particular patient reported more than one bleeding event during the follow up period, we included the most severe self- . We also adjusted for a history of bleeding problems, heart failure, history of PCI, and history of acute coronary syndrome 26 .
Statistical Analysis
Baseline characteristics, including all demographic, socioeconomic, and clinical factors were compared between patients with vs. without DM using Chi square test for categorical variables and Mann-Whitney U test for continuous variables as the continuous variables were not parametrically distributed.
The incidence of bleeding over the year following index PCI, as assessed by a BARC score ≥1, was compared between groups at each follow-up time point using the Chi square test. Assumptions of logistic modeling were met, including an adequate sample size, lack of multicollinearity among predictor variables, and lack of unexplained outliers. Accordingly, a multivariable logistic regression model was used to assess the independent association between DM status and bleeding outcomes over the year following index PCI.
Subsequently, we performed a sensitivity analysis to explore bleeding incidence at follow up when excluding bruising in the definition of bleeding (i.e. BARC ≥1 minus bruising as the primary outcome). This analysis was considered informative as healthcare providers rarely recommend antiplatelet therapy discontinuation as a consequence of bruising, which is a common patient concern while on antiplatelet therapy. Because we included bruising within our initial definition of a BARC ≥1 bleeding event, it was important to further explore whether removing the commonly reported bruising from outcome definition would change our primary result. Were the results to remain largely unchanged following this sensitivity analysis, this would further support the clinical actionability of our results by demonstrating that pure bleeding outcomes (without bruising included in the definition) are still different in patients with and without DM. Lastly, to further exclude the possibility that bleeding differences found were in part explained by different antiplatelet therapy discontinuance rates, we analyzed discontinuance between patients with and without DM who were discharged on DAPT.
In the original dataset, missing baseline data (mean number of missing items per patient=0.17) were imputed using IVEware (Imputation and Variance Estimation Software;
University of Michigan's Survey Research Center, Institute for Social Research, Ann Arbor, MI). Little's MCAR test was significant, suggesting that data were not missing completely at random. Single imputation was used to account for missing variables, as the rate of missing data for any individual variable was <10%. Because the baseline characteristics of patients who did and did not have follow up data at 12 months were statistically different, we evaluated the effect of missingness on bleeding outcomes and found that the Cohen's d was small for each of the significantly different baseline characteristics. As the effect was small (small effect size considered to be <0.1), we deferred further analyses of missingness.
All analyses were conducted using SPSS Statistics 22, and statistical significance was determined by a 2-sided p-value of <0.05.
RESULTS

Study Population
Of 3299 patients from 10 U.S. sites (Supplemental Table A Figure 4 ). Patients who were missing 12 month outcomes data were more likely to be younger, non-white race, smokers, and of lower socioeconomic status compared with those in the analytic cohort (Supplemental Table 3 ) In addition, patients with missing data were less likely to be treated with drug eluting stent, had lower hemoglobin levels, and were more likely to report bleeding issues at baseline. 
Bleeding Outcomes
In unadjusted analyses, patients with DM had lower reported bleeding over the year following PCI using the BARC ≥1 classification (DM vs. no DM: BARC ≥1: 77.7% vs.
87.6%, p<0.001), but not when using the BARC ≥2 classification (BARC ≥ 2: 4.5% vs. elective; p-interaction=0.324).
Subsequently, we performed a sensitivity analysis to explore bleeding incidence at follow up after excluding bruising from the definition of bleeding (i.e. BARC ≥1 minus bruising as the primary outcome). This analysis yielded lower bleeding outcomes in patients with DM, as compared with without DM (OR 0.77, 95% CI 0.62-0.96; Figure 5 ).
We completed a second sensitivity analysis assessing crude bleeding rates (BARC ≥1
including bruising) at 1,6 and 12 months, including all patients discharged on DAPT, without excluding patients who were not on DAPT at 12 month follow up. In patients with DM, there was no difference in the odds of reporting bleeding at 1 month. 
Dual Anti platelet Therapy Discontinuance
The rate of DAPT discontinuation was similar between patients with and without DM at one-year follow up (13.6% vs. 14.2% respectively, p=0.719). For patients not on a thienopyridine or aspirin at follow up, a follow up question regarding reason for 
Prior Studies
Our study supports and extends the prior literature, which has been primarily limited to sub-studies of clinical trials. 18, 19 These results advance knowledge by highlighting the independent association of DM with bleeding outcomes, an area that was not previously explored. The OPS/PRISM registry provided a unique cohort for investigation of our research questions by including rich documentation of patient characteristics and clinical variables from representative US centers, promoting the external generalizability of our findings. Our results of less bleeding with DAPT among those patients with DM demonstrate that the risk-benefit balance of prolonged DAPT may be even more favorable than previously recognized in this group of patients.
In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON TIMI-38), patients with a myocardial infarction treated with PCI were randomized to DAPT with prasugrel vs. clopidogrel. In pre-specified subgroup analyses, major bleeding rates (2.6% vs.
2.0%) and major or minor bleeding rates (4.8% vs. 4.2%) were similar between subjects with and without DM, respectively. However, patients with DM did not experience a significant increase in bleeding with more aggressive platelet inhibition (i.e., prasugrel vs. clopidogrel), in contrast with the bleeding outcomes among patients without DM. 20 As a result, the net clinical benefit of prasugrel compared with clopidogrel was greater in patients with DM, compared with patients without DM.
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In contrast to the results of TRITON-TIMI 38, the results of the PLATelet inhibition and patient Outcomes (PLATO) study, which randomized patients following acute coronary syndrome to DAPT with ticagrelor vs. clopidogrel, showed that the rates of major bleeding not related to bypass surgery were higher in patients with vs.
without DM (5.2% vs. 3.8%) with no differential effect of ticagrelor vs. clopidogrel on either ischemic or bleeding outcomes. Both of these large clinical trials examined bleeding outcomes in patients admitted for acute coronary syndrome, while our study enrolled a broader range of indications for PCI, including, but not limited to, acute coronary syndrome.
Some of the differences between our results and those from the 2 trials above, likely result from the bleeding definitions used (TRITON and PLATO trials classified bleeding events within major and minor categories), as we found no difference between rates of BARC ≥2 bleeding between groups. Another important distinction lies in that our study represented a real-world cohort, including patients who otherwise are not eligible for or choose to participate in clinical trials. As such, we believe that our study substantially expands the current understanding of the bleeding outcomes, and the risk-benefit balance, of long-term DAPT in this important patient group.
Potential Mechanisms for Lower Bleeding Outcomes
The results of lower bleeding rates with DAPT use in PCI patients with DM vs. those who did not have DM could be explained by increased platelet reactivity in the setting of hyperglycemia and insulin resistance, 27, 28 thereby exposing patients with DM to a higher risk of ischemic events and a lower risk of bleeding while receiving long-term DAPT.
Additionally, although we adjusted for body mass index in our multivariable model, obesity has been described to attenuate bleeding, 29 and could therefore in part explain improved bleeding outcomes in patients with DM (who are more commonly overweight or obese).
Future studies are therefore needed to elucidate whether or not bleeding outcomes are related in a "dose-dependent" fashion to level of glycemic control in patients with DM. This information could further our understanding of the level of platelet inhibition in diabetic patients with suboptimal glycemic control, as compared with those who are euglycemic.
Clinical Implications
Appropriate patient selection for prolonged DAPT is critically important, as one must weigh the additional ischemic benefits against the risks of bleeding that are associated with DAPT. This risk-benefit balance was recently highlighted by the Dual Antiplatelet Therapy (DAPT) trial, in which prolonged DAPT for 30 vs. 12 months after DES implantation led to reduced ischemic outcomes but more bleeding. 30 Ideally, patients who are selected for prolonged DAPT should be those at higher risk of recurrent thrombotic events and who also have a lower risk of bleeding. In many situations, such as advanced age, the factors that increase ischemic risk also increase bleeding risk, making the decision to prescribe prolonged DAPT more challenging. In the setting of DM, the ischemic benefits of prolonged DAPT are well-established-both in terms of DES use (which requires longer DAPT vs. BMS) for reduction of restenosis and for greater absolute risk reduction of general ischemic events, such as stent thrombosis and myocardial infarction. Collectively, these data reinforce the preferential use of DES over BMS in patients with DM by supplementing the well-known greater absolute risk reduction in restenosis in patients with DM by also defining a lower risk of bleeding, the adverse consequence of using DES and prolonged DAPT.
Our findings are also meaningful in the context of patient counseling as they may inform shared decision making choices between patient and provider ahead of the PCI procedure. Given this information, patients with DM may better understand their odds of adverse events following a common and necessary therapy.
Our findings of less bleeding with DAPT among those patients with DM demonstrate that the risk-benefit balance of prolonged DAPT may be even more favorable than previously recognized. Accordingly, future studies are needed to replicate these findings in an acute coronary syndrome and elective PCI cohort. In addition, future investigations should be conducted to elucidate the impact of glycemic control on bleeding outcomes in patients with DM. Lastly, examining the type of anti platelet medication prescribed would allow us to examine the association of use of particular anti platelet agents with bleeding with more granularity.
Limitations
Our findings should be considered in the context of several potential limitations. First, bleeding events were self-reported, which may have led to over-or under-estimation of bleeding events. However, the presence of DM would not be expected to lead to differential reporting bias. Second, DAPT adherence was also self-reported, as we did not have access to pharmacy data to verify the exact duration of DAPT use. Lastly, due to the observational nature of our study, there is the possibility of residual confounding despite extensive adjustment. Such potential confounders may include markers of DM control, which were not collected in our registry. Measurement of hemoglobin A1c (a marker of average DM) control over the 2-3 months preceding A1c analysis), insulin use and presence of microalbuminuria may have informed our understanding of the gradation of bleeding outcomes based on strata of DM control. Another potential confounder that was not captured in our database was hemoglobin measurement at follow up. This value could have potentially extended our ability to validate patient self-report of bleeding events during the follow up period. Last, there is a potential that patients may have discontinued DAPT or dropped out of the study due to bleeding episodes. Differential DAPT discontinuance between patients with and without DM due to bleeding events may have skewed our observed bleeding rates to over-or under-estimate bleeding outcomes.
Conclusions
In this real-world PCI registry, patients with DM experienced significantly lower risk of bleeding on long-term DAPT than those without DM over the year following index PCI.
As patients with DM also derive greater ischemic benefit from DES, which require prolonged DAPT, our findings suggest that the balance between benefit and risk of this therapeutic approach is likely even more favorable in patients with DM than previously described. "I was never told to take it" "I was told to take it only for a specified time"
APPENDIX
"My doctor told me to stop" "I stopped on my own because of cost" "I stopped on my own because of side effects" *************Now going to compare nonparametrically distributed continuous variables at baseline between patients with and without DM********************** DATASET ACTIVATE DataSet1. *****************checking assumptions for logistic regression modeling (sample size is adequate, no multicollinearity, no unexplained outliers**************** REGRESSION /MISSING PAIRWISE /STATISTICS COEFF OUTS R ANOVA COLLIN TOL
